Why Turning Point Brands may be a better investment than Altria

Aug.30.2022
Why Turning Point Brands may be a better investment than Altria
Turning Point Brands stock (TPB) is currently a better choice due to lower valuation compared to Altria (MO).

Compared to tobacco giant Altria (NYSE: MO), smaller tobacco company Turning Point Brands (NYSE: TPB) is currently a better choice due to its lower relative valuation of 0.8x compared to Altria's 3.2x tracking revenue. This valuation gap is primarily due to Altria's superior earnings capabilities.


Looking at stock returns, despite a 3% decline year-to-date, Altria has outperformed Turning Point Brands, which has fallen 36%, as well as the broader S&P 500 index, which has dropped 13%. However, there is more to consider and in the section below, we will discuss why we believe TPB stock will offer better returns than MO stock over the next three years. We compared a range of factors, such as historical revenue growth, return, and valuation multiples, in our interactive dashboard analysis of Altria versus Turning Point Brands: which stock is the better choice? A summary of the partial analysis is provided below.


1. Turning point brands experience decent revenue growth.


Two companies have both released their sales growth in the past twelve months. Despite this, Turning Point Brands' revenue growth of 5.0% is higher than Altria's 0.2%. Even when we look at a longer time frame, Turning Point Brands has performed well, with its sales growing at an average annual rate of 10.2% to $445.5 million in 2021, up from $332.7 million in 2018, while Altria's sales have grown by 0.9% to $26 billion currently, up from $25.4 billion in 2018.


Altria sells tobacco products in the US market and generates revenue from the sale of both smoking and smokeless products. However, their revenue growth was impacted during the pandemic due to supply disruptions. Last year, Altria sold its wine business for $1.2 billion and has since focused more on smoking and smokeless products. For a more in-depth understanding of the company's sales performance, our Altria revenue dashboard is available.


Turning Point Brands sells vapor products, chewing tobacco, rolling papers, and cigar wraps, among other items. Its Zig-Zag division, which includes rolling papers, cigar wraps, and smoking accessories, has been driving the company's sales growth in recent years. However, due to regulatory changes, Turning Point Brands' vapor business has recently declined, particularly after the implementation of a new rule in the Prevent All Cigarette Trafficking (PACT) Act at the end of last year. Following recent regulatory changes, it has become challenging to mail anything related to vapor to either businesses or consumers.


Sales for Turning Point Brands' NewGen division, which includes vapor products, decreased significantly by 41% in the first half of this year, comprising only 23% of its total net sales. In comparison, last year's sales for the same period accounted for 35%. Conversely, the company's other divisions, Zig-Zag and Stoker, have consistently performed well, and this trend is expected to continue in the coming years.


Looking towards the future, Turning Point Brands is expected to experience faster revenue growth over the next three years than Altria. The table below summarizes our revenue expectations for both companies over the next three years, based on Trefis machine learning analysis. Turning Point Brands is projected to have a compound annual growth rate of 15.2%, while Altria's compound annual growth rate is only expected to be 1.6%.


Please note that when predicting future income, we have different methods for companies that have been negatively impacted by Covid compared to those that have not been affected or have had a positive impact. For companies negatively affected by Covid, we consider the quarterly revenue recovery trajectory to predict a return to pre-Covid income levels. After the recovery point, we apply the average annual growth rate observed in the three years before Covid to simulate a return to normalcy. For companies that have experienced positive revenue growth during Covid, we consider the average annual growth before Covid, with some weight placed on growth during Covid and the past 12 months.


Altria earns more money" in standard journalistic English.


In the past 12 months, Altria's operating profit margin was 17.6%, surpassing Turning Point Brands' margin of 12.6%. This is a significant improvement from pre-pandemic 2019 figures, which stood at 3.1% and 4.5% respectively. Additionally, Altria's free cash flow profit margin of 32.6% is much better than Turning Point Brands' 11.1%.


Our dashboard for Altria's revenue and Turning Point Brand's revenue has more detailed information. In terms of financial risk, Altria has a much lower debt-to-equity ratio of 34% compared to Turning Point Brand's 94%. Additionally, Altria's cash-to-asset ratio of 13% is lower than the latter's 20%, indicating that Altria has a better debt position, while Turning Point Brands has more cash reserves.


万物之网" can be translated to "The Network of All Things" in standard journalistic English.


We can see that Turning Point Brands has exhibited stronger revenue growth, has more cash reserves, and is relatively undervalued. On the other hand, Altria has a better debt situation and higher profits. Looking ahead, based on the P/S ratio and due to the high volatility of the P/E and P/EBIT ratios, we believe that Turning Point Brands is the better choice between the two.


The table below summarizes our revenue and return expectations for Altria and Turning Point Brands over the next three years, indicating that the expected return for Turning Point Brands during this period is 58%, while the expected return for Altria's stock is only 5%. This means that according to Trefis machine learning analysis, investors would be better off purchasing TPB instead of MO, and this analysis also provides more details on how we arrived at these figures.


While TPB's stock performance may be better than MO's, the Covid-19 crisis has caused many pricing discontinuities, which can provide attractive trading opportunities. For example, you would be surprised at how counterintuitive the stock valuations of Philip Morris and Coca-Cola are.


Statement


This article is compiled from third-party information and is intended for industry communication and learning purposes only.


This article does not represent the views of 2FIRSTS, and we cannot confirm the authenticity or accuracy of its contents. The compilation of this article is solely for the purpose of industry exchange and research.


Due to limitations in our translation abilities, the translated article may not fully convey the same meaning as the original. Please refer to the original article for accuracy.


2FIRSTS maintains full alignment with the Chinese government regarding any domestic, Hong Kong, Macau, Taiwan, and foreign-related positions and statements.


The copyright of compiled information belongs to the original media and author. If there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

U.S. Ninth Circuit Upholds FDA Denial of MH Global’s Flavored Vape PMTA Applications
U.S. Ninth Circuit Upholds FDA Denial of MH Global’s Flavored Vape PMTA Applications
The U.S. Court of Appeals for the Ninth Circuit upheld the FDA’s denial of MH Global LLC’s applications to market flavored electronic nicotine delivery systems (ENDS). The court ruled that FDA’s comparative-efficacy framework, which requires applicants to show that flavored products provide greater cessation or switching benefits than tobacco-flavored alternatives, is consistent with the Tobacco Control Act’s “appropriate for the protection of the public health” standard. The court also found that FDA was not required to establish the framework through notice-and-comment rulemaking.
Aug.26
BAT UK Director Tolga Kilic Says Illicit Nicotine Market Squeezes Legal Retailers Amid Rising Compliance Costs
BAT UK Director Tolga Kilic Says Illicit Nicotine Market Squeezes Legal Retailers Amid Rising Compliance Costs
UK retail publication Grocery Trader has published a viewpoint article from Tolga Kilic, Commercial Director for BAT UK & Ireland, discussing the impact of illicit nicotine products on legitimate retail channels. Kilic said illegal vapes and other illicit nicotine products create competitive pressure for compliant retailers and called for stronger market controls and supply-chain oversight. The comments come as the UK advances policies including the disposable vape ban and Vaping Products Duty, creating a more complex operating environment for legal vape retailers.
Jul.28
Juul Sublicense Reshapes Vuse Alto Patent Bill as Court Ends R.J. Reynolds’ 5.25% Royalty Obligation to Altria
Juul Sublicense Reshapes Vuse Alto Patent Bill as Court Ends R.J. Reynolds’ 5.25% Royalty Obligation to Altria
According to Law360 on August 31, 2026, a federal judge in North Carolina ruled that a patent sublicense between R.J. Reynolds Vapor Co. and Juul Labs Inc. relieves Reynolds of its obligation to continue paying royalties to Altria Client Services LLC over Vuse Alto. A jury had previously found that Vuse Alto infringed three Altria patents and awarded approximately $95.2 million in past damages, after which Reynolds was ordered to pay an ongoing royalty equal to 5.25% of positive net sales. The new ruling finds that a valid sublicense can eliminate future infringement, potentially ending what Altria described as hundreds of millions of dollars in future royalties.
Sep.01
French Anti-Tobacco Group Questions PMI’s IQOS “Curiosity” Campaign Over Potential Youth Appeal
French Anti-Tobacco Group Questions PMI’s IQOS “Curiosity” Campaign Over Potential Youth Appeal
According to French anti-tobacco group Générations Sans Tabac, Philip Morris International’s (PMI) IQOS “Curiosity” campaign has drawn attention from public health advocates. The group argues that the campaign uses themes including curiosity, exploration and lifestyle branding that could increase interest among younger audiences. PMI has positioned IQOS as a key part of its smoke-free product strategy, while France maintains strict restrictions on tobacco and nicotine product marketing. The debate highlights ongoing tensions between heated tobacco branding strategies and public health concerns in Europe.
Jul.24
Product | BAT Expands VELO Travellers’ Collection With Mexico, Spain and Sweden Summer Edition Nicotine Pouches
Product | BAT Expands VELO Travellers’ Collection With Mexico, Spain and Sweden Summer Edition Nicotine Pouches
British American Tobacco (BAT) Global Travel Retail has expanded the VELO Travellers’ Collection with three new Summer Editions: Mexico, Spain and Sweden. Inspired by destination themes, the new nicotine pouch variants are designed for global travel-retail channels. The launch further strengthens VELO’s positioning as a travel-retail exclusive product collection.
Aug.27
Product | Philip Morris Japan Launches Ginza-Exclusive IQOS ILUMA i PRIME, Limited to 1,814 Units at First Global Flagship
Product | Philip Morris Japan Launches Ginza-Exclusive IQOS ILUMA i PRIME, Limited to 1,814 Units at First Global Flagship
Philip Morris Japan (PMJ) launched the IQOS ILUMA i PRIME Ginza Limited Model Set in Tokyo on September 4, 2026, alongside the opening of IQOS Flagship Ginza, the brand’s first global flagship store. The Oasis Blue edition is limited to 1,814 individually numbered units, with the figure derived from the store’s address at Ginza 1-8-14. The set also includes two Yamanaka-nuri glasses and special packaging, priced at JPY 11,980 and sold exclusively at the Ginza flagship.
Sep.07